In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 6, 2001, Pages 1860-1867

  Livermore, David M ^a   Carter, Michael W ^a   Bagel, Simone ^b   Wiedemann, Bernd ^b   Baquero, Fernando ^o   Loza, Elena ^c   Endtz, Hubert P ^d   Van Braak, Nicole Den ^d   Fernandes, Clarence J ^e   Fernandes, Lorna ^e   Frimodt Moller, Niels ^g   Rasmussen, Laura S ^g   Giamarellou, Helen ^h   Giamarellos Bourboulis, Evangelos ^h   Jarlier, Vincent ⁱ   Nguyen, Jacqueline ⁱ   Nord, Carl Erik ^j   Struelens, Marc J ^k   Nonhoff, Caire ^k   Turnidge, John ^f   Bell, Jan ^f   Zbinden, Reinhard ^l   Pfister, Stefan ^o   Mixson, Lori ^m   Shungu, Daniel L ⁿ   more..

^a CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

^b Pharmazeutische Mikrobiologie   (Germany)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^g STATENS SERUM INSTITUT   (Denmark)

^h UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^l UNIVERSITY OF ZURICH   (Switzerland)

^m Biometrics Research   (United States)

ⁿ MERCK RESEARCH LABORATORIES   (United States)

^o NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTRIAXONE; ERTAPENEM; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; CLOSTRIDIUM DIFFICILE; DRUG POTENCY; ENTEROBACTERIACEAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0035017496     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.6.1860-1867.2001     Document Type: Article

References (24)

1. Bornet, C., A. Davin-Regli, C. Bosi, J. M. Pages, and C. Bollet. 2000. Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J. Clin. Microbiol. 38:1048-1052.
2. Bradford, P. A., C. Urban, A. Jaiswal, N. Mariano, B. A. Rasmussen, S. J. Projan, J. J. Rahal, and K. Bush. 1995. SHV-7, a novel cefotaxime-hydrolyzing β-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob. Agents Chemother. 39:899-905.
3. Charrel, R. N., J. M. Pages, P. De Micco, and M. Mallea. 1996. Prevalenee of outer membrane porin alteration in β-lactam-antibiotic-resistant Enterobacter aerogenes. Antimicrob. Agents Chemother. 40:2854-2858.
4. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
5. De Gheldre, Y., N. Maes, F. Rost, R. De Ryck, P. Clevenbergh, J. L. Vincent, and M. J. Struelens. 1997. Molecular epidemiology of an outbreak of multidrug-resistant Enterobacter aerogenes infection and in vivo emergence of imipenem resistance. J. Clin. Microbiol. 35:152-160.
6. Edwards, J. R., and M. J. Betts. 2000. Carbapenems: the pinnacle of the β-lactam antibiotics or room for improvement? J. Antimicrob. Chemother. 45:1-4.
7. Fuchs, P. C., A. L. Barry, and S. D. Brown. 1999. In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests. J. Antimicrob. Chemother. 43:703-706.
8. Gill, C. J., J. J. Jackson, L. S. Gerckens, B. A. Pelak, R. K. Thompson, J. G. Sundelof, H. Kropp, and H. Rosen. 1998. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345). Antimicrob. Agents Chemother. 42:1996-2001.
9. King, A., C. Boothman, and I. Phillips. 1989. Comparative in-vitro activity of meropenem on clinical isolates from the United Kingdom. J. Antimicrob. Chemother. 24(Suppl. A):31-45.
10. Kohler, J., K. L. Dorso, K. Young, G. G. Hammond, H. Rosen, H. Kropp, and L. L. Silver. 1999. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase-and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 43:1170-1176.
11. Livermore, D. M. 1995. β-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584.
12. Livermore, D. M. 1996. Are all β-lactams created equal? Scand. J. Infect. Dis. Suppl. 101:33-43.
13. Livermore, D. M., and N. Woodford. 2000. Carbapenemases: a problem in waiting? Curr. Opin. Microbiol. 3:489-495.
14. National Committee for Clinical Laboratory Standards. 2000. Performance standards for antimicrobials disk susceptibility tests, 7th ed. Approved standard M2-A7. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. National Committee for Clinical Laboratory Standards. 2000. Methods for antimicrobial susceptibility testing for anaerobic bacteria, 4th ed. Approved standard M11-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
17. National Committee for Clinical Laboratory Standards. 2000. Development of in vitro susceptibility testing criteria and quality control parameters, 2nd ed. Approved guideline M23-A2. National Committee for Clinical Laboratory Standards. Wayne, Pa.
18. Quinn, J. P. 1998. Clinical strategies for serious infection: a North American perspective. Diagn. Microbiol. Infect. Dis. 31:389-395.
19. Raimondi, A., A. Traverso, and H. Nikaido. 1991. Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins. Antimicrob. Agents Chemother. 35:1174-1180.
20. Rasmussen, B. A., and K. Bush. 1997. Carbapenem-hydrolyzing β-lactamases. Antimicrob. Agents Chemother. 41:223-232.
21. Rasmussen, B. A., Y. Gluzman, and F. P. Tally. Cloning and sequencing of the class β-lactamase gene (ccrA) from Bacteroides fragilis TAL3636. Antimicrob. Agents Chemother. 34:1590-1592.
22. Spratt, B. G. 1994. Resistance to antibiotics mediated by target alterations. Science 264:388-393.
23. Walsh, T. R., R. A. Stunt, J. A. Nabi, A. P. MacGowan, and P. M. Bennett. 1997. Distribution and expression of β-lactamase genes among Aeromonas spp. J. Antimicrob. Chemother. 40:171-178.
24. Yang, Y., B. A. Rasmussen, and K. Bush. 1992. Biochemical characterization of the metallo-β-lactamase CcrA from Bacteroides fragilis TAL3636. Antimicrob. Agents Chemother. 36:1155-1157.